{
    "id": "35a6e911-500f-ef0d-e063-6294a90a07e1",
    "indications": {
        "text": "imcivree indicated reduce excess body weight maintain weight reduction long term adults pediatric patients aged 2 years older syndromic monogenic obesity due : bardet-biedl syndrome ( bbs ) [ ( 2.1 ) ] pro-opiomelanocortin ( pomc ) , proprotein convertase subtilisin/kexin type 1 ( pcsk1 ) , leptin receptor ( lepr ) deficiency determined fda-approved test demonstrating variants pomc , pcsk1 , leprgenes interpreted pathogenic , likely pathogenic , uncertain significance ( vus ) [ ( 2.1 ) ] . limitations : imcivree notindicated treatment patients following conditions imcivree would expected effective : obesity due suspected pomc , pcsk1 , lepr deficiency pomc , pcsk1 , leprvariants classified benign likely benign types obesity related bbs pomc , pcsk1 , lepr deficiency , including obesity associated genetic syndromes general ( polygenic ) obesity",
        "doid_entities": [
            {
                "text": "obesity (DOID:9970)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9970"
            },
            {
                "text": "bardet-biedl syndrome (DOID:1935)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1935"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "bardet-biedl syndrome",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_110"
            }
        ]
    },
    "contraindications": {
        "text": "select patients treatment diagnosis bbs genetically determined suspected deficiency pomc , pcsk1 , lepr . ( 2.1 ) recommended starting injected subcutaneously : adults pediatric patients aged 12 years older 2 mg ( 0.2 ml ) daily 2 weeks . ( 2.2 ) pediatric patients aged 6 less 12 years 1 mg ( 0.1 ml ) daily 2 weeks . ( 2.3 ) pediatric patients aged 2 less 6 years 0.5 mg ( 0.05 ml ) daily 2 weeks . ( 2.4 ) recommended maintenance adults pediatric patients aged 6 years older 3 mg ( 0.3 ml ) injected subcutaneously daily . ( 2.2 , 2.3 ) recommended maintenance dose pediatric patients aged 2 less 6 years determined body weight . ( 2.4 ) recommended patients renal impairment , full prescribing information . ( 2.5 ) titration recommendations , full prescribing information . ( 2.2 , 2.3 , 2.4 , 2.5 , 2.6 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "imcivree injection supplied : 10 mg/ml , clear slightly opalescent , colorless slightly yellow solution 1-ml multiple-dose vial single patient package 1 multiple-dose vial : ndc 72829-010-01 store unopened imcivree vials refrigerator 2\u00b0c 8\u00b0c ( 36\u00b0f 46\u00b0f ) original carton . removal refrigerator , vials may kept temperatures ranging refrigerated room temperature ( 2\u00b0c 25\u00b0c [ 36\u00b0f 77\u00b0f ] ) 30 days brief excursions 30\u00b0c ( 86\u00b0f ) . vial punctured ( opened ) , discard 30 days . table 14for summary storage conditions imcivree . store vials original carton . table 14 recommended storage imcivree vials 1if necessary , imcivree may stored room temperature ( \u226430\u00b0c [ \u226486\u00b0f ] ) returned refrigerated conditions storage condition unopened vial opened vial 2\u00b0c 8\u00b0c ( 36\u00b0f 46\u00b0f ) expiration date 30 days , expiration date ( whichever earlier ) 2\u00b0c 25\u00b0c ( 36\u00b0f 77\u00b0f ) excursions permitted 30\u00b0c ( 86\u00b0f ) 1 30 days , expiration date ( whichever earlier ) 30 days , expiration date ( whichever earlier ) > 30\u00b0c ( > 86\u00b0f ) discard discard",
    "adverseReactions": "imcivree contraindicated patients prior serious hypersensitivity reaction setmelanotide excipients imcivree . serious hypersensitivity included anaphylaxis [ ( 5.3 ) ] .",
    "ingredients": [
        {
            "name": "SODIUM N-(CARBONYL-METHOXYPOLYETHYLENE GLYCOL 2000)-1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE",
            "code": "3L6NN8ZZKU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "CARBOXYMETHYLCELLULOSE",
            "code": "05JZI7B19X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_85146"
        },
        {
            "name": "PHENOL",
            "code": "339NCG44TV",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15882"
        },
        {
            "name": "BENZYL ALCOHOL",
            "code": "LKG8494WBH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17987"
        },
        {
            "name": "EDETATE DISODIUM",
            "code": "7FLD91C86K",
            "drugbank_id": "https://go.drugbank.com/drugs/DB13404"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "SETMELANOTIDE",
            "code": "N7T15V1FUY",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11700"
        }
    ],
    "organization": "Rhythm Pharmaceuticals, Inc",
    "name": "Imcivree",
    "effectiveTime": "20250331",
    "indications_original": "IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to:\n                  \n                     Bardet-Biedl syndrome (BBS)\n  \n   [see Dosage and Administration (\n   \n    2.1)]\n  \n   \n                     \n                     Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in\n  \n   POMC, PCSK1, or LEPRgenes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS)\n  \n   [see Dosage and Administration (\n   \n    2.1)].\n  \n   \n                     \n                  \n                  \n                     Limitations of Use:\n                  \n                  IMCIVREE is\n \n  notindicated for the treatment of patients with the following conditions as \n    IMCIVREE would not be expected to be effective:\n\n \n                  \n                     Obesity due to suspected POMC, PCSK1, or LEPR deficiency with\n  \n   POMC,\n  \n   PCSK1, or\n  \n   LEPRvariants classified as benign or likely benign\n \n  \n                     Other types of obesity not related to BBS or POMC, PCSK1, or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity",
    "contraindications_original": "Select patients for treatment who have a clinical diagnosis of BBS or who have genetically determined or suspected deficiency of POMC, PCSK1, or LEPR. ( 2.1 ) Recommended starting dosage injected subcutaneously for: Adults and pediatric patients aged 12 years and older is 2 mg (0.2 mL) once daily for 2 weeks. ( 2.2 ) Pediatric patients aged 6 to less than 12 years is 1 mg (0.1 mL) once daily for 2 weeks. ( 2.3 ) Pediatric patients aged 2 to less than 6 years is 0.5 mg (0.05 mL) once daily for 2 weeks. ( 2.4 ) Recommended maintenance dosage for adults and pediatric patients aged 6 years and older is 3 mg (0.3 mL) injected subcutaneously once daily. ( 2.2 , 2.3 ) Recommended maintenance dose for pediatric patients aged 2 to less than 6 years is determined by body weight. ( 2.4 ) For recommended dosage in patients with renal impairment, see Full Prescribing Information. ( 2.5 ) For titration and administration recommendations, see Full Prescribing Information. ( 2.2 , 2.3 , 2.4 , 2.5 , 2.6 )",
    "warningsAndPrecautions_original": "IMCIVREE injection is supplied as:\n                  \n                     10 mg/mL, clear to slightly opalescent, colorless to slightly yellow solution in a 1-mL multiple-dose vial for single patient use\n                     Package of 1 multiple-dose vial: NDC 72829-010-01\n                  \n                  Store unopened IMCIVREE vials in the refrigerator at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F) in the original carton. After removal from the refrigerator, vials may be kept at temperatures ranging from refrigerated to room temperature (2\u00b0C to 25\u00b0C [36\u00b0F to 77\u00b0F]) for up to 30 days with brief excursions up to 30\u00b0C (86\u00b0F). After the vial is punctured (opened), discard after 30 days. See\n \n  Table 14for a summary of storage conditions for IMCIVREE. Store vials in the original carton.\n\n \n                  \n                     Table 14 Recommended Storage for IMCIVREE Vials\n                  \n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 1If necessary, IMCIVREE may be stored at room temperature (\u226430\u00b0C [\u226486\u00b0F]) and then returned to refrigerated conditions\n    \n     \n                           \n                        \n                     \n                     \n                        \n                           \n                              Storage Condition\n                           \n                           \n                              Unopened Vial\n                           \n                           \n                              Opened Vial\n                           \n                        \n                        \n                           2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F)\n                           Until the expiration date\n                           Up to 30 days, OR \n       Until the expiration date \n       (whichever is earlier)\n    \n                        \n                        \n                           2\u00b0C to 25\u00b0C (36\u00b0F to 77\u00b0F) with excursions permitted up to 30\u00b0C (86\u00b0F)\n    \n     1\n                           \n                           Up to 30 days, OR \n       Until the expiration date \n       (whichever is earlier)\n    \n                           Up to 30 days, OR \n       Until the expiration date \n       (whichever is earlier)\n    \n                        \n                        \n                           >30\u00b0C (>86\u00b0F)\n                           Discard and do not use\n                           Discard and do not use",
    "adverseReactions_original": "IMCIVREE is contraindicated in patients with a prior serious hypersensitivity reaction to setmelanotide or any of the excipients in IMCIVREE. Serious hypersensitivity reactions have included anaphylaxis\n \n  [see Warnings and Precautions (\n  \n   5.3)].",
    "drug": [
        {
            "name": "Imcivree",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        }
    ]
}